UK markets closed

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4700+0.1000 (+7.33%)
As of 03:15PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 287.15M
Enterprise value 292.34M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.32
Price/book (mrq)N/A
Enterprise value/revenue 1.50
Enterprise value/EBITDA -72.24

Trading information

Stock price history

Beta (5Y monthly) 0.84
52-week change 322.64%
S&P500 52-week change 322.38%
52-week high 32.4800
52-week low 30.7800
50-day moving average 31.5598
200-day moving average 31.3258

Share statistics

Avg vol (3-month) 35.04M
Avg vol (10-day) 32.59M
Shares outstanding 5209.6M
Implied shares outstanding 6209.6M
Float 8190.2M
% held by insiders 11.93%
% held by institutions 126.61%
Shares short (15 Apr 2024) 413.69M
Short ratio (15 Apr 2024) 41.42
Short % of float (15 Apr 2024) 46.60%
Short % of shares outstanding (15 Apr 2024) 46.53%
Shares short (prior month 15 Mar 2024) 410.13M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -26.68%
Operating margin (ttm)5.26%

Management effectiveness

Return on assets (ttm)-9.31%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)194.62M
Revenue per share (ttm)1.04
Quarterly revenue growth (yoy)0.70%
Gross profit (ttm)N/A
EBITDA -6.87M
Net income avi to common (ttm)-51.92M
Diluted EPS (ttm)-0.2800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)42.92M
Total cash per share (mrq)0.2
Total debt (mrq)104.18M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.18
Book value per share (mrq)-0.16

Cash flow statement

Operating cash flow (ttm)-23.38M
Levered free cash flow (ttm)22.11M